使用abiraterone治療抗去勢型前列腺癌病人:彰化基督教醫院之經驗
方琬云、石宏仁、王百孚
彰化基督教醫院 外科部 泌尿科
An experience with abiraterone as treatment for metastatic castration-resistant prostate cancer: Changhua Christian Hospital experience
Wan-yun Fang, Hung-Jen Shih, Pai-Fu Wang
Division of Urology, Department of Surgery, Changhua Christian Hospital
Purpose:
To evaluate the tumor responses of abiraterone in castration-resistant prostate cancer (CRPC) patients.
Materials and Methods:
Retrospective analysis of 9 consecutive patients with metastatic CRPC undergoing treatment with abiraterone. Treatment effectiveness and safety analyses regarding baseline characteristics of patients (age, prior treatments, basal PSA, performance status, pain, metastasis) were conducted. All patients were monitored for secondary declines in PSA, radiological tumor regression and side effects.
Results:
A total of 8 patients had a PSA decline that was confirmed by a second PSA level at least 4 weeks later. In all, 4 patients had a confirmed 50% PSA decline. Treatment was well tolerated, with no grade 3 and grade 4 adverse events.
Conclusion:
The treatment with abiraterone has been effective in our series, with a tolerability considerably higher than what other studies published.